Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)
November 10, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences to Host Investor Call
November 04, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
November 03, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
November 02, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
October 26, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference
October 19, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery,...
Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients
October 12, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
September 29, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan
September 28, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
“Effect of nasal anti-CD3 (foralumab) in animal model of Progressive Multiple Sclerosis (MS)” poster exhibit“Effect of nasal anti-CD3 (foralumab) in healthy subjects” poster exhibit“Effect of nasal...
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
September 23, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...